Castle Biosciences (CSTL) Capital Expenditures (2018 - 2026)

Castle Biosciences (CSTL) has 9 years of Capital Expenditures data on file, last reported at $12.5 million in Q1 2026.

• Quarterly Capital Expenditures rose 287.16% year-over-year to $12.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.4 million (up 350.83% YoY) and the FY2025 annual result came in at $2.1 million, changed N/A from the prior year.
• Capital Expenditures improved to $12.5 million in Q1 2026 per CSTL's latest filing, from -$26.7 million in the prior quarter.
• The five-year high for Capital Expenditures was $22.0 million in Q3 2025, with the low at -$26.7 million in Q4 2025.
• Average Capital Expenditures over 5 years is $1.7 million, with a median of $3.2 million recorded in 2025.
• Year-over-year, Capital Expenditures soared 10331.25% in 2023 and slumped 647.3% in 2024.
• Castle Biosciences' Capital Expenditures stood at -$2.4 million in 2022, then jumped by 254.88% to $3.8 million in 2023, then plunged by 647.3% to -$20.8 million in 2024, then slipped by 28.73% to -$26.7 million in 2025, then jumped by 146.61% to $12.5 million in 2026.
• Business Quant data shows CSTL's Capital Expenditures at $12.5 million in Q1 2026, -$26.7 million in Q4 2025, and $22.0 million in Q3 2025.